TY - JOUR
T1 - Infectious complications of chronic lymphocytic leukaemia
T2 - Pathogenesis, spectrum of infection, preventive approaches
AU - Morrison, Vicki A.
PY - 2010/3/1
Y1 - 2010/3/1
N2 - Infectious complications continue to be a major cause of morbidity and mortality in patients with chronic lymphocytic leukaemia (CLL). The pathogenesis of infections in these patients is multifactorial, related to inherent immune defects and therapy-related immunosuppression. Hypogammaglobulinaemia is an important predisposing factor for infection in all patients. The use of the purine analogues such as fludarabine, and monoclonal antibodies such as rituximab and alemtuzumab, has introduced a new spectrum of infectious complications caused by pathogens such as Pneumocystis, Listeria, mycobacteria, herpesviruses Candida and Aspergillus, related to the cellular immune suppression induced by these agents. This review focusses on the pathogenesis and risk factors for infections in patients with CLL, the spectrum of infectious complications and preventive approaches to infection in these patients, using antimicrobial and immunoglobulin prophylaxis and vaccination strategies.
AB - Infectious complications continue to be a major cause of morbidity and mortality in patients with chronic lymphocytic leukaemia (CLL). The pathogenesis of infections in these patients is multifactorial, related to inherent immune defects and therapy-related immunosuppression. Hypogammaglobulinaemia is an important predisposing factor for infection in all patients. The use of the purine analogues such as fludarabine, and monoclonal antibodies such as rituximab and alemtuzumab, has introduced a new spectrum of infectious complications caused by pathogens such as Pneumocystis, Listeria, mycobacteria, herpesviruses Candida and Aspergillus, related to the cellular immune suppression induced by these agents. This review focusses on the pathogenesis and risk factors for infections in patients with CLL, the spectrum of infectious complications and preventive approaches to infection in these patients, using antimicrobial and immunoglobulin prophylaxis and vaccination strategies.
KW - alemtuzumab
KW - fludarabine
KW - hypogammaglobulinaemia
KW - immunoglobulin
KW - pentostatin
KW - prophylaxis
UR - http://www.scopus.com/inward/record.url?scp=77956632397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956632397&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2009.12.004
DO - 10.1016/j.beha.2009.12.004
M3 - Review article
C2 - 20620978
AN - SCOPUS:77956632397
SN - 1521-6926
VL - 23
SP - 145
EP - 153
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 1
ER -